Paper42469871
TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.
Ke ZY and 7 others. J Transl Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia. Papers, record 42469871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42469871
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Carrier Proteins | Major topic |
| Ubiquitin Thiolesterase | Major topic |
| Nuclear Proteins | Major topic |
| Repressor Proteins | Major topic |
| Humans | |
| Animals | |
| Cell Line, Tumor | |
| Ubiquitination | |
| Apoptosis | |
| Cell Proliferation | |
| Protein Stability | |
| Prognosis | |
| Mice | |
| Protein Binding | |
| Transcription Factors | |
| Homeodomain Proteins |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2026MSXM004 | Medical Research Project of Chongqing Municipal Science and Technology Commission and Health Commission | PubMed | ||
| CSTB2023NSCQ-MSX0222 | Chongqing Natural Science Foundation Project | PubMed | ||
| YJJL2024070 | Scientific Research Project of Yongchuan Hospital Affiliated to Chongqing Medical University | PubMed | ||
| YJJL2024073 | Scientific Research Project of Yongchuan Hospital Affiliated to Chongqing Medical University | PubMed | ||
| Chongqing public health key specialty (discipline) project | Chongqing public health key specialty (discipline) project | PubMed |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32324863 | TRIM24 facilitates antiviral immunity through mediating K63-linked TRAF3 ubiquitination. | J Exp Med | 2020 | https://conductscience.org/library/papers/32324863 | PubMed |
| 2 | 41034872 | Magnetically navigated nano-PROTAC ameliorates acute lung injury. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/41034872 | PubMed |
| 3 | 17369846 | CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation. | Oncogene | 2007 | https://conductscience.org/library/papers/17369846 | PubMed |
| 4 | 24409330 | Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. | PLoS One | 2014 | https://conductscience.org/library/papers/24409330 | PubMed |
| 5 | 29627320 | TRIM24 promotes hepatocellular carcinoma progression via AMPK signaling. | Exp Cell Res | 2018 | https://conductscience.org/library/papers/29627320 | PubMed |
| 6 | 29507391 | Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. | Nat Chem Biol | 2018 | https://conductscience.org/library/papers/29507391 | PubMed |
| 7 | 22666376 | Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. | PLoS One | 2012 | https://conductscience.org/library/papers/22666376 | PubMed |
| 8 | 32015510 | Inhibition of the deubiquitinase USP10 induces degradation of SYK. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32015510 | PubMed |
| 9 | 39048965 | Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39048965 | PubMed |
| 10 | 40975747 | TRIM24-mediated K27-linked ubiquitination of ULK1 alleviates energy stress-induced autophagy and promote prostate cancer growth in the context of SPOP mutation. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/40975747 | PubMed |
| 11 | 31044085 | USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. | Cell Discov | 2019 | https://conductscience.org/library/papers/31044085 | PubMed |
| 12 | 34066940 | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34066940 | PubMed |
| 13 | 37633647 | Ubiquitination and deubiquitination: Implications on cancer therapy. | Biochim Biophys Acta Gene Regul Mech | 2023 | https://conductscience.org/library/papers/37633647 | PubMed |
| 14 | 20096447 | USP10 regulates p53 localization and stability by deubiquitinating p53. | Cell | 2010 | https://conductscience.org/library/papers/20096447 | PubMed |
| 15 | 38994801 | p110CUX1 promotes acute myeloid leukemia progression via regulating pyridoxal phosphatase expression and activating PI3K/AKT/mTOR signaling pathway. | Mol Carcinog | 2024 | https://conductscience.org/library/papers/38994801 | PubMed |
| 16 | 21164480 | TRIM24 links a non-canonical histone signature to breast cancer. | Nature | 2010 | https://conductscience.org/library/papers/21164480 | PubMed |
| 17 | 35627217 | USP10 as a Potential Therapeutic Target in Human Cancers. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/35627217 | PubMed |
| 18 | 32694757 | Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways. | Acta Pharmacol Sin | 2021 | https://conductscience.org/library/papers/32694757 | PubMed |
| 19 | 32547943 | CUX1, A Controversial Player in Tumor Development. | Front Oncol | 2020 | https://conductscience.org/library/papers/32547943 | PubMed |
| 20 | 40517136 | USP10 promotes the progression and attenuates gemcitabine chemotherapy sensitivity via stabilizing PLK1 in PDAC. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40517136 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42469871
GET https://conductscience.org/api/papers/v1/42469871/references?page=2